Drugs / ALG-055009
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06959888 | Mar → May 2025 | — | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06191991 | Nov 2023 | — | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05090111 | Dec 2021 → Jun 2023 | metabolic dysfunction-associated steatohepatitis | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT06342947 | Apr → Aug 2024 | metabolic dysfunction-associated steatohepatitis | Aligos Therapeutics | Completed | Met primary |
News releases announcing trial results or a regulatory action · 17
| Date | Issuer | Release |
|---|---|---|
| 2025-12-11 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at HEP-DART 2025 aligos.com ↗
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists |
| 2025-05-08 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at the EASL Congress 2025 aligos.com ↗
These data continue to demonstrate the best-in-class potential of ALG-055009 across the cardio-metabolic space. |
| 2025-04-23 | Aligos Therapeutics | Results Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025 aligos.com ↗
ALG-055009, a novel thyroid hormone receptor beta agonist, demonstrated significant reductions in atherogenic lipids/lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis in the Phase 2a HERALD |
| 2025-03-26 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at APASL 2025 aligos.com ↗
Additionally, the HERALD data from the Phase 2a study of ALG-055009 in MASH subjects demonstrated robust reductions in liver fat |
| 2024-11-19 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 aligos.com ↗
12-weeks of once daily ALG-055009 treatment in MASH patients met the primary endpoint, with robust reductions in liver fat content at Week 12. |
| 2024-09-19 | Aligos Therapeutics | Results Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH aligos.com ↗
ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFF |
| 2024-03-27 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies aligos.com ↗
The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids |
| 2023-12-07 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009) aligos.com ↗
We are also pleased for the opportunity to present findings from the Phase 1 trial of our THR-β agonist, ALG-055009, including favorable safety, lipid-lowering activity and differentiated pharmacology and pharmacokinetics, compared to competitor THR-β agonists. |
| 2023-11-13 | Aligos Therapeutics | Results Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile aligos.com ↗
ALG-055009 was well tolerated with no safety signals identified |
| 2023-09-21 | Aligos Therapeutics | Regulatory Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009 aligos.com ↗
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced it has received clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) for ALG-055009, it’s thyroid hormone receptor beta agonist (THR-β), intended for the treatment of nonalcoholic steatohepatitis (NASH). |
| 2023-03-29 | Aligos Therapeutics | Results Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference aligos.com ↗
We’re pleased to show at the conference that ALG-055009 has demonstrated a favorable safety and pharmacokinetic profile in healthy volunteers and subjects with hyperlipidemia,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics. |
| 2023-02-16 | Aligos Therapeutics | Results Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver aligos.com ↗
At this year’s meeting, we look forward to sharing data demonstrating that ALG-055009, our thyroid hormone receptor-beta (THR-β) agonist in development for NASH, showed promising anti-lipid effects in subjects with hyperlipidemia |
| 2022-11-04 | Aligos Therapeutics | Results Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022 aligos.com ↗
Multiple ascending dose (MAD) data from the ongoing Phase 1 study ALG-055009-301 (NCT05090111) demonstrate that treatment for 14 days in subjects with hyperlipidemia resulted in reduced triglyceride, low-density lipoprotein (LDL), and apolipoprotein B levels in a generally dose-dependent manner. |
| 2022-10-21 | Aligos Therapeutics | Results Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022 aligos.com ↗
Finally, we are excited to share the excellent pharmacokinetic (PK) properties, well tolerated safety profile and reductions in various lipid levels we have observed after hyperlipidemic subjects received multiple doses of our thyroid hormone beta agonist, ALG-055009. |
| 2022-06-22 | Aligos Therapeutics | Results Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress™ 2022 aligos.com ↗
In the first clinical data presentation from our NASH program, preliminary data on multiple ascending doses of ALG-055009 in subjects with hyperlipidemia demonstrated favorable pharmacokinetics, safety, and anti-lipid activity |
| 2021-11-12 | Aligos Therapeutics | Results Aligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio at The Liver Meeting® 2021 aligos.com ↗
We are also excited to present our THR-β agonist drug candidate, ALG-055009, that has a favorable preclinical pharmacokinetic profile that is supportive of once-daily dosing in humans and appears to have a low risk of drug-drug interactions. |
| 2019-11-11 | Aligos Therapeutics | Results Aligos Therapeutics Presents NASH Asset Development Update at The Liver Meeting® 2019 aligos.com ↗
In a diet-induced obese murine model, ALG-055009 reduced cholesterol in a pronounced and sustained fashion after a single dose and demonstrated excellent bioavailability when administered orally. |
All press releases naming this drug 27 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALG-055009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06959888 ↗ |
| Route | Oral | “Oral dose(s) of ALG-055009 in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days” NCT05090111 ↗ |